| Literature DB >> 31214517 |
Majed F Alghoribi1,2, Michel Doumith1,2, Maha Alrodayyan1,2, Maha Al Zayer1,2, Wolfgang L Köster3, Abdulhai Muhanna4, Sameera M Aljohani1,2,5, Hanan H Balkhy1,2,5, Taseen S Desin1,2.
Abstract
Non-typhoidal Salmonella (NTS) strains are Gram negative bacterial pathogens that are associated with foodborne illness worldwide. During the process of infection, Salmonella uses two molecular injectisomes known as Type 3 Secretion Systems (T3SS) to secrete virulence factors that are encoded by Salmonella Pathogenicity Island-1 (SPI-1) and SPI-2 into host cells. These secretion systems play a major role in virulence, as shown in various animal models, but little is known about their role in human infections. In Saudi Arabia, NTS strains frequently cause human infections but data regarding these pathogenic strains is fairly limited. The aim of this study was to characterize Salmonella human clinical isolates in Riyadh, Saudi Arabia, by determining their serotype, testing for the presence of SPI-1 and SPI-2 genes and to determine the antibiotic resistance profiles of these strains. Using the rapid Check and Trace Salmonella ™ (CTS) system our results demonstrate that S. Enteritidis and S. Typhimurium were the predominant serovars, followed by S. Livingstone, S. Kentucky and S. Poona among a list of 36 serovars reported for the first time in the country. In addition, SPI-1 genes were detected in 99% of the isolates, while the sifA gene (SPI-2) was not detected in 13.5% of the isolates. These results suggest that both the SPI-1 and SPI-2 virulence determinants are important for human infection. Moreover, we report the presence of a Multi-Drug (MDR) carbapenem resistant S. Kentucky isolate harboring the bla OXA-48 gene not reported previously in Saudi Arabia.Entities:
Keywords: SP-1; SPI-2; Salmonella; Type 3 secretion systems; serotyping
Mesh:
Substances:
Year: 2019 PMID: 31214517 PMCID: PMC6554431 DOI: 10.3389/fcimb.2019.00187
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Primers used in this study to detect antimicrobial resistance determinants and SPI genes.
| F: CAT TTT CGT GTC GCC CTT AT | 793 | 55 | Lynne et al., | |
| F: ATG AAA AAC ACA ATA CAT ATC | 830 | 55 | Wang et al., | |
| F: TTG GTG GCA TCG ATT ATC GG | 743 | 54.5 | Poirel et al., | |
| F: GGT TAA AAA ATC ACT GCG TC | 873 | 55 | Wang et al., | |
| F: ACC GAG CCC ACG CTC AA | 221 | 55 | Wang et al., | |
| F: AGA GTG CAA CGG ATG ATG | 868 | 55 | Wang et al., | |
| F: GTG GTG GAT GCC AGC ATC C | 915 | 55 | Wang et al., | |
| F: CGC TTC CCG TTA ACA AGT AC | 420 | 58 | Weill et al., | |
| F: ATG CGT TAT ATT CGC CTG T | 750 | 54.5 | Hujer et al., | |
| F: GAT GGT GTT TGG TCG CAT A | 390 | 52 | Dolejska et al., | |
| F: GGAATAGAGTGGCTTAATTCT C | 188 | 52 | Dolejska et al., | |
| F: GGT TTG GCG ATC TGG TTT TC | 622 | 54.5 | Poirel et al., | |
| F: TGG CCA GAA CTG ACA GGC AAA | 462 | 64 | Perez-Perez and Hanson, | |
| F: GCT GCT CAA GGA GCA CAG GAT | 520 | 64 | Perez-Perez and Hanson, | |
| F: AAC TTT CAC AGG TGT GCT GGG T | 405 | 64 | Perez-Perez and Hanson, | |
| F: AAC AGC CTC AGC AGC CGG TTA | 346 | 64 | Perez-Perez and Hanson, | |
| F: TCG GTA AAG CCG ATG TTG CGG | 302 | 64 | Perez-Perez and Hanson, | |
| F: AAC ATG GGG TAT CAG GGA GAT G | 190 | 64 | Perez-Perez and Hanson, | |
| F: TGG GCA ATG ACT GGA ACA | 431 | 55 | Wang et al., | |
| F: ATG AGC GAT ATG GCA GAG CG | 413 | 62 | Wang et al., | |
| F: CCA CTT ACT TCC AGT GCG GA | 2113 | 60 | This study | |
| F: TTC ATC GCA TCT TTC CCG GT | 2010 | 60 | This study | |
| F: CAT CAG GAG GCA TTC TGA AGAT | 712 | 60 | This study | |
| F: CGT GAC GTC TGA GAA AGC GT | 1000 | 59.5 | This study | |
| F: ATA GCG TTC CAG GTC GTG TC | 668 | 60 | This study | |
Prevalence of Salmonella serotypes associated with Human infections in Riyadh (2015–2017).
| 80 (40) | |
| 27 (13.5) | |
| 10 (5) | |
| 9 (4.5) | |
| 9 (4.5) | |
| 5 (2.5) | |
| 5 (2.5) | |
| 4 (2) | |
| 3 (1.5) | |
| 3 (1.5) | |
| 3 (1.5) | |
| 3 (1.5) | |
| 3 (1.5) | |
| 3 (1.5) | |
| 2 (1) | |
| 2 (1) | |
| 2 (1) | |
| 2 (1) | |
| 2 (1) | |
| 2 (1) | |
| 2 (1) | |
| 1 (0.5) | |
| 1 (0.5) | |
| 1 (0.5) | |
| 1 (0.5) | |
| 1 (0.5) | |
| 1 (0.5) | |
| 1 (0.5) | |
| 1 (0.5) | |
| 1 (0.5) | |
| 1 (0.5) | |
| 1 (0.5) | |
| 1 (0.5) | |
| 1 (0.5) | |
| 1 (0.5) | |
| 1(0.5) | |
| Non- | 2 (1) |
| Unknown | 2 (1) |
Prevalence of Salmonella serotypes based on the source of the clinical sample.
| Agona | 5 | 4 | 0 | 0 | 0 | 1 | 0 |
| Chailey | 3 | 2 | 0 | 0 | 0 | 0 | 1 |
| Corvallis | 3 | 3 | 0 | 0 | 0 | 0 | 0 |
| Enteritidis | 80 | 66 | 2 | 0 | 2 | 1 | 9 |
| Galiema | 3 | 1 | 0 | 0 | 0 | 0 | 2 |
| Gaminara | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Give | 4 | 4 | 0 | 0 | 0 | 0 | 0 |
| Kentucky | 9 | 9 | 0 | 0 | 0 | 0 | 0 |
| Kottbus | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Livingstone | 10 | 10 | 0 | 0 | 0 | 0 | 0 |
| Minnesota | 2 | 1 | 0 | 0 | 0 | 1 | 0 |
| Muenchen | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Newport | 5 | 5 | 0 | 0 | 0 | 0 | 0 |
| Obogu | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Ohio | 3 | 3 | 0 | 0 | 0 | 0 | 0 |
| Orion | 3 | 3 | 0 | 0 | 0 | 0 | 0 |
| Poona | 9 | 7 | 1 | 0 | 0 | 0 | 1 |
| Saintpaul | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Schwarzengrund | 3 | 3 | 0 | 0 | 0 | 0 | 0 |
| Typhimurium | 27 | 21 | 2 | 1 | 0 | 1 | 2 |
| Urbana | 2 | 1 | 0 | 0 | 0 | 0 | 1 |
| Others | 15 | 13 | 2 | 0 | 0 | 0 | 0 |
| Non-enterica | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Unknown (ST3374) | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Total | 200 | 170 | 7 | 1 | 2 | 4 | 16 |
Others includes serotypes for which there was only one strain positive for that particular serotype: S. Altona, S. Anatum, S. Blockley, S. Caen, S. Eastbourne, S. Haifa, S. Havana, S. Infantis, S. Manhattan, S. Mbandaka, S. Molade, S. Montevideo, S. Pomona, S. Sandiego, and S. Telhashomer.
S. enterica serotypes that lack SPI virulence genes.
| Caen | 1 | 1/1 (100%) | 1 | |
| Corvallis | 3 | 2/3 (67%) | 2 | |
| Enteritidis | 80 | 2/80 (2.5%) | 2 | |
| Havana | 1 | 1/1 (100%) | 1 | |
| Kentucky | 9 | 1/9 (11%) | 8 | |
| 7/9 (78%) | ||||
| Livingstone | 10 | 5/10 (50%) | 5 | |
| Mbandaka | 1 | 1/1 (100%) | 1 | |
| Molade | 1 | 1/1 (100%) | 1 | |
| Obogu | 2 | 1/2 (50%) | 1 | |
| Ohio | 3 | 3/3 (100%) | 3 | |
| Orion | 3 | 1/3 (33%) | 1 | |
| Schwarzengrund | 3 | 1/3 (33%) | 1 | |
| Typhimurium | 27 | 1/27 (3.7%) | 1 | |
| Non-enterica subspecies | 2 | 1/2 (50%) | 1 | |
| 1/2 (50%) | 1 | |||
| Unknown | 2 | 1/2 (50%) | 1 | |
| Total | 148 | 31 |
Prevalence of antibiotic resistance among human clinical Salmonella isolates.
| NIT | 34 | 17 |
| AMP | 27 | 13.5 |
| CF | 20 | 10 |
| TGC | 20 | 10 |
| CIP | 17 | 8.5 |
| SXT | 16 | 8 |
| GEN | 9 | 4.5 |
| AMC | 7 | 3.5 |
| CAZ | 4 | 2 |
| CRO | 4 | 2 |
| TZP | 4 | 2 |
| AMK | 2 | 1 |
| FOX | 2 | 1 |
| FEP | 1 | 0.5 |
| IPM | 1 | 0.5 |
| MEM | 1 | 0.5 |
Antibiogram for Salmonella strains that are resistant to antibiotics.
| Agona | CIP-TGC-SXT | 3 | 1 |
| Blockley | CIP-TGC-NIT | 3 | 1 |
| Caen | TGC | 1 | 1 |
| Chailey | NIT | 1 | 1 |
| Enteritidis | AMP | 1 | 1 |
| Give | AMP-CF-CAZ-CRO-GEN | 5 | 1 |
| Haifa | AMP-CF-GEN | 3 | 1 |
| Havana | AMP-AMC-TZP-CF-CIP-SXT | 6 | 1 |
| Infantis | CF | 1 | 1 |
| Kentucky | GEN-CIP | 2 | 2 |
| Livingstone | NIT | 1 | 1 |
| Minnesota | AMP-AMC-CF-FOX-CAZ-CRO-CIP-TGC | 8 | 2 |
| Newport | TGC | 1 | 3 |
| SaintPaul | AMP | 1 | 1 |
| Typhimurium | AMP | 1 | 1 |
| Total | 77 |
Genotypes for Salmonella strains with resistance to β-lactam antibiotics and Ciprofloxacin.
| Agona | 117 | < 2 | < 2 | < 4 | 4 | < 4 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | >4 | S83F/D87N | T57S/S80I | |
| 145 | >32 | 16 | 16 | 4 | < 4 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | >4 | S83F/D87N | T57S/S80I | ||
| 189 | >32 | >32 | >128 | 16 | 8 | < 1 | < 1 | 2 | < 0.25 | < 0.25 | >4 | S83F/D87N | T57S/S80I | ||
| Blockley | 3 | 8 | < 2 | 8 | 4 | 8 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | >4 | S83F/D87G | T57S/S80R | |
| Enteritidis | 4 | < 2 | < 2 | < 4 | 4 | < 4 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | 2 | S83Y | ||
| 50 | >32 | 4 | < 4 | 16 | < 4 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | < 0.25 | ||||
| 118 | 4 | < 2 | < 4 | 4 | < 4 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | 1 | S83Y | |||
| 121 | >32 | 4 | < 4 | 4 | < 4 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | < 0.25 | ||||
| 161 | >32 | 8 | < 4 | 4 | < 4 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | 1 | WT | |||
| 191 | 8 | < 2 | < 4 | 8 | < 4 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | 1 | S83Y | |||
| Give | 154 | >32 | 4 | < 4 | >64 | < 4 | >64 | >64 | 4 | < 0.25 | < 0.25 | < 0.25 | |||
| Haifa | 173 | >32 | 4 | < 4 | 8 | < 4 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | < 0.25 | |||
| Havana | 87 | >32 | >32 | >128 | >64 | 8 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | 1 | S83F | ||
| Kentucky | 14 | < 2 | < 2 | < 4 | 2 | < 4 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | >4 | S83F/D87N | T57S/S80I | |
| 22 | >32 | >32 | 32 | >64 | < 4 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | < 0.25 | S83F/D87G | T57S/S80I | ||
| 35 | >32 | >32 | >128 | >64 | 16 | 16 | >64 | 32 | 8 | 8 | >4 | S83F/D87G | |||
| 61 | >32 | >32 | >128 | >64 | 16 | 2 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | ||||
| 179 | < 2 | < 2 | < 4 | 2 | < 4 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | >4 | S83F/D87N | T57S/S80I | ||
| Minnesota | 76 | >32 | >32 | < 4 | >64 | >64 | 16 | 8 | < 1 | < 0.25 | < 0.25 | 1 | WT | ||
| 95 | >32 | >32 | < 4 | >64 | >64 | 16 | 8 | < 1 | 0.5 | < 0.25 | 1 | WT | |||
| Newport | 181 | >32 | 16 | < 4 | 4 | < 4 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | < 0.25 | |||
| Saintpaul | 124 | >32 | 4 | < 4 | 4 | < 4 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | < 0.25 | |||
| Typhimurium | 20 | >32 | 16 | 8 | < 2 | < 4 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | < 0.25 | |||
| 27 | >32 | 4 | < 4 | 8 | < 4 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | < 0.25 | ||||
| 34 | >32 | 8 | < 4 | 4 | < 4 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | < 0.25 | ||||
| 38 | >32 | 8 | < 4 | 8 | < 4 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | >4 | S83F/D87G | S80I | ||
| 55 | >32 | 8 | < 4 | 8 | < 4 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | < 0.25 | ||||
| 59 | >32 | 8 | < 4 | 8 | < 4 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | < 0.25 | ||||
| 92 | >32 | 4 | < 4 | 4 | < 4 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | < 0.25 | ||||
| 137 | >32 | 8 | < 4 | 8 | < 4 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | < 0.25 | ||||
| 163 | >32 | 8 | < 4 | 8 | < 4 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | < 0.25 | ||||
| 167 | >32 | < 4 | 4 | 8 | < 4 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | < 0.25 | ||||
| 184 | >32 | 8 | < 4 | 4 | < 4 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | < 0.25 | ||||
| 190 | >32 | 8 | < 4 | 8 | < 4 | < 1 | < 1 | < 1 | < 0.25 | < 0.25 | < 0.25 |
Resistant to a given antibiotic as per CLSI standards.